BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Nirmal Bang initiates Aurobindo Pharma with buy
Aurobindo Pharma has transformed itself from an API player to an established formulations player in the generic space. There are multiple growth levers in place now with the change in business mix. A strong new drug application pipeline to drive US sales. Value stock at 18 times its FY2018 estimated earnings per share of Rs 49.7.